A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System:The MOBYBOX Trial

Recruiting now

Conditions studied: Cardiac Failure, Respiratory Failure, Cardio-Respiratory Failure, Imminent Cardiorespiratory or Respiratory Failure

In brief

The purpose of this study is to evaluate prospectively the safety and performance of the MOBYBOX System in the veno-arterial configuration in patients with cardiorespiratory failure or in the veno-venous configuration in patients with severe respiratory failure.

Key facts

Study ID

NCT04183660

Run by

Hemovent GmbH

People needed

60

Starts

2024-04-30

Expected to finish

2026-12-01

Last updated by the study team

2025-05-31

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with cardiac, respiratory or cardiorespiratory failure or imminent failure and 1 of the 5 following sets of findings:
• A Murray score ≥ 3.0 and/or severe hypoxemia with A PaO2/FIO2 > 100 mm on 0.9 FIO2;
• Uncompensated hypercapnia with pH <7.2 despite a Pplateau > 30 cm H20;
• Significant air leak/bronchopleural fistula;
• Need for intubation in a patient on lung transplant list;
• Immediate/risk of cardiac or respiratory collapse (pulmonary embolus, blocked airway, blocked blood flow, unresponsive to optimal care);
• Written consent of the patient or the legal guardian or external consulting physician as designated and approved by the Ethics Committee.

You may not qualify if…

• High pressure ventilation (FIO2 > 0.9 and Pplateau > 30 cm H2O) or high FIO2 requirements for more than 7 days;
• Severe intracranial bleeding, which precludes the use of anticoagulation therapy or any other inability to be anticoagulated
• Excessive weight (> 180 Kg)
• Severe irreversible brain injury (e.g., hypoxic brain injury)
• Inability to accept blood products;
• Any condition or organ dysfunction that would limit the likelihood of overall benefit from ECMO, such as severe, irreversible brain injury, hepatic and/or renal failure, or untreatable metastatic cancer;
• Immunosuppression with an absolute neutrophil count < 400/mm3;
• Patient has been treated with ECMO ≤ 48 hours.
• For veno-veno ECMO in the setting of respiratory failure the following exclusion criteria apply:
• Severe pulmonary hypertension (mPAP > 50 mm Hg)
• Severe right or left sided heart failure (EF < 25%)
• For veno-arterial ECMO in the setting of cardiac insufficiency:
• Severe aortic regurgitation
• Aortic dissection.
• The patient is moribund, or the patient has severe or deteriorating damage in critical body systems.
• Patient is participating in an investigational drug or device study trial that has not reached the primary endpoint or that interferes with the current study endpoints.
• Any condition that in the judgment of the investigators would interfere with the subject's ability to provide informed consent, comply with study instructions, place the subject at increased risk, or which might confound interpretation of study results.

Where it is running

• Medizinische Hochschule Hannover — Hanover, Lower Saxony, Germany (enrolling)
• Universitätsklinikum Essen — Essen, North Rhine-Westphalia, Germany (enrolling)
• Universitätsklinikum Halle — Halle, Saxony-Anhalt, Germany (enrolling)
• Helios Klinikum Erfurt — Erfurt, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.